Schiweck, Carmen http://orcid.org/0000-0003-4215-0448
Claes, Stephan
Van Oudenhove, Lukas
Lafit, Ginette
Vaessen, Thomas
de Beeck, Gommaar Op http://orcid.org/0000-0002-5182-5016
Berghmans, Raf
Wijkhuijs, Annemarie
Müller, Norbert
Arolt, Volker
Drexhage, Hemmo http://orcid.org/0000-0001-8513-5323
Vrieze, Elske
Funding for this research was provided by:
EC | EC Seventh Framework Programm | FP7 Health (222963)
EC | Horizon 2020 Framework Programme (754740)
Article History
Received: 1 August 2019
Revised: 14 July 2020
Accepted: 22 July 2020
First Online: 24 August 2020
Change Date: 26 September 2020
Change Type: Update
Change Details: The original HTML version of this Article was updated shortly after publication to add the Projekt DEAL funding acknowledgement.
Conflict of interest
: C.S. has no conflict of interest. S.C. is a senior clinical researcher from the Fund for Scientific Research Flanders (FWO Vlaanderen). L.V.O. has received an unrestricted grant from Nestlé and serves as a consultant for Danone, none of which has relevance to the present work. V.A. has received compensations for his contributions as a member of advisory boards and for presentations for the following companies: Astra-Zeneca, Eli Lilly, Janssen-Cilag, Lundbeck, Otsuka, Servier and Trommsdorff. These co-operations have no relevance to the work that is covered in the paper. H.A.D. has received funding from the EU (MOODINFLAME, PSYCHAID and MOODSTRATIFICATION) and the Dutch Fund for Scientific Research (NWO), Medical Sciences. G.O.D.B. and R.B. work for apDIA, an advanced practical diagnostics company. T.V., G.L., N.M. and E.V. have no conflict of interest to declare.